Can you extract Mounjaro from the pen — and is it safe to try?

Why would someone want to extract medicine from a Mounjaro pen in the first place?

This question comes up for a handful of reasons. Some people notice what looks like medicine left in the cartridge after the fourth dose and wonder whether it is going to waste. Others have heard of clinics or pharmacies that repackage injectable medicines into individual syringes, and assume the same must be possible here. A smaller group are searching because they found a pen secondhand and want to use it, which raises a different and serious problem altogether.

The KwikPen holds a small overfill beyond its four marked doses. That overfill is not a bonus dose; it is a manufacturing standard that ensures each of the four doses is accurate. You can read more about what that remaining medicine in the pen actually represents, the short version is that it is not meant to be used.

The Mounjaro KwikPen is a single-patient, pre-filled device. Eli Lilly designed it so that each weekly dose is dialled and delivered without the user ever contacting the medicine directly. The needle is integrated, retractable, and single-use. The device is not a vial; there is no rubber septum to pierce with an external syringe. Trying to access the cartridge would mean physically compromising the pen's structure, which voids any assurance about sterility or dose accuracy. The NHS patient information for tirzepatide makes clear that the pen should be used exactly as the Patient Information Leaflet describes, and that includes using the pen's own needle mechanism for every injection.

Is there any legitimate medical situation where the medicine would be drawn up differently?

Not in standard UK practice for weight management. Tirzepatide for weight loss is licensed and supplied only in the KwikPen format; the SmPC published on the eMC specifies subcutaneous injection via the pen device. There is no licensed UK presentation of tirzepatide as a vial or ampoule for self-injection, which means there is no approved method for a patient to draw it into a separate syringe at home.

You may have seen references online to compounded tirzepatide, preparations made outside the licensed supply chain, sometimes supplied in vials with separate syringes. These are not the same product. They are not approved by the MHRA, they are not subject to the same manufacturing standards, and the MHRA has warned specifically about illegally traded weight-loss medicines entering the UK market. A pen that arrives in plain, untracked packaging with no pharmacy verification behind it is a significant safety concern, not a bargain. If you want to understand more about where genuine Mounjaro comes from and what the licensed supply chain looks like, that page sets it out clearly.

The standard Mounjaro injection process is designed to be straightforward: attach a fresh needle, dial the dose, choose a site (abdomen, thigh or upper arm), inject, and dispose of the needle in a sharps bin. That is the full extent of what you need to manage. If you need needles for the pen, replacement needles are available separately. There is nothing in the approved process that requires handling the medicine outside the pen.

What should you do if something goes wrong with your pen or a dose seems to have been missed?

Pens can occasionally malfunction, the plunger sticks, the dose counter does not move, or the medicine does not appear to have been delivered. This is uncommon, but it does happen. The right response is never to try to retrieve or replicate the dose manually.

First, check the Patient Information Leaflet that comes with your pen; it includes a troubleshooting section covering common device issues. If the pen has clearly failed to deliver a dose, contact your prescriber. They will advise whether the dose should be taken as soon as possible or whether the weekly schedule should simply continue from the next planned injection day, that timing call is theirs to make, not yours to guess at.

If you notice what looks like bruising or a skin reaction at the injection site, that is separate from the question of whether the dose was delivered. Injection-site bruising is relatively common, particularly in the early weeks, and is usually related to injection technique rather than a pen fault. Rotating sites and using a fresh needle each time both help, and if technique is something you have questions about, that is exactly the kind of thing to raise with your prescriber.

Keep your pen in the fridge door between doses (2–8°C, away from the freezer compartment), most people find the door shelf the easiest habit to build, since it is visible every day. Never try to warm the pen by running it under hot water or placing it near a heat source; the SmPC specifies the permitted room-temperature window, and exceeding it affects the medicine.

What if you are not currently on Mounjaro but are thinking about starting?

Tirzepatide is a prescription-only medicine, and the consultation process exists because a prescriber needs to assess your full health picture before approving it. BMI is one part of that assessment; your medical history, current medications and any relevant conditions all feed into the decision. Our Mounjaro overview covers the eligibility criteria and what the treatment involves in plain terms.

For context on costs, this page on Mounjaro pricing in the UK explains the market honestly, including what headline prices often leave out. And if you want to see the full range of weight-loss treatment options we offer, that is a good starting point before a consultation.

At nume, a real prescriber reads your consultation the same day, not software, not a queue. If you are clinically suitable, your prescription is issued and your treatment is dispatched the same day, arriving free the next working day by tracked DPD. Check your eligibility and start your free consultation at our treatment page.